H.R. 6130: ASAP Act
Sponsor
Vern Buchanan
Republican · FL-16
Bill Progress
Latest Action · Nov 19, 2025
Referred to Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. for review
Medicare should cover earlier Alzheimer’s blood tests
Why it matters
Starting January 1, 2028, Medicare would cover qualifying early Alzheimer’s and dementia screening tests instead of leaving many patients to pay out of pocket. That could make earlier answers easier to get—especially if a blood-based test is enough to start the process.
H.R. 6130 is a narrow Medicare coverage bill. It would add a permanent Medicare benefit for early detection tests used to identify Alzheimer’s disease or related dementias before symptoms are advanced.
The bill is built around tests that already went through a federal review process. It explicitly covers genomic sequencing blood or blood product tests, and it lets the Department of Health and Human Services recognize other comparable tests too.
That matters because a blood-based test is a very different experience from navigating a patchwork of specialist visits, imaging, and out-of-pocket bills. If this passes, Medicare would start paying for qualifying tests furnished on or after January 1, 2028.
The practical reach of the bill depends on how broadly HHS defines “equivalent” tests. Congress sets the benefit, but regulators will still decide how many newer screening tools actually make it into covered Medicare care.
H.R. 6130 Bill Summary
What H.R. 6130 actually does.
Early dementia screening becomes a Medicare benefit
The bill adds Alzheimer’s and related dementia early detection screening tests to Medicare’s covered services, making this a standing benefit rather than a temporary pilot.
Coverage starts in 2028
Medicare would only cover qualifying tests furnished on or after January 1, 2028.
Blood-based tests are directly included
The bill specifically includes genomic sequencing blood or blood product tests aimed at detecting pre-symptomatic or early-stage Alzheimer’s disease or related dementias.
Other screening tools can qualify too
HHS could allow other tests if they produce comparable results. The bill lists examples such as single-analyte tests, cell-free nucleic acid analysis, multiplex panels, whole genome sequencing, protein expression testing, whole exome, whole transcriptome, and some medical imaging.
Only federally reviewed tests make the cut
A test must already be cleared, classified, or approved through an FDA pathway before Medicare coverage applies.
Payment runs through Medicare’s lab-test system
Instead of creating a separate reimbursement structure, the bill routes payment through Medicare’s existing clinical laboratory test framework.
Who benefits from H.R. 6130?
Medicare patients looking for answers earlier
If you are on Medicare and worried about memory changes, this bill could make a qualifying early screening test part of covered care starting in 2028.
Families planning for dementia care
Earlier detection can mean more time to plan for treatment, caregiving, housing, and finances before symptoms become more severe.
Patients who may prefer a blood-based test
The bill is designed around blood or blood product testing, which could give some patients a simpler entry point into dementia screening.
Labs and test developers with approved products
Companies with tests that already passed a federal review pathway would gain a clearer Medicare payment route if their products meet the bill’s standards.
Who is affected by H.R. 6130?
CMS and Medicare administrators
Medicare would need to stand up a new covered service and fold qualifying tests into its existing laboratory payment system by 2028.
HHS regulators deciding what counts as equivalent
The department would have major discretion over which newer tests beyond the named blood-based category qualify for coverage.
Test makers without federal clearance or approval
If a company’s screening tool has not gone through an FDA review pathway, it would not qualify for Medicare coverage under this bill.
Patients seeking screening before 2028
The bill does not create immediate coverage. Anyone seeking these tests before January 1, 2028 could still face today’s access and payment barriers.
HR6130 Legislative Journey
House: Committee Action
Nov 19, 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
About the Sponsor
Vern Buchanan
Republican, Florida's 16th congressional district · 19 years in Congress
Committees: Joint Committee on Taxation, Ways and Means
View full profile →
Cosponsors (157)
This bill has 157 cosponsors: 97 Democrats, 59 Republicans, 1 Independent, reflecting bipartisan support. Cosponsors represent 40 states: Alaska, Alabama, Arizona, and 37 more.
Paul Tonko
Democrat · NY
Timothy Kennedy
Democrat · NY
Jennifer Kiggans
Republican · VA
Ritchie Torres
Democrat · NY
Gus Bilirakis
Republican · FL
Brian Fitzpatrick
Republican · PA
Mike Kelly
Republican · PA
Mike Ezell
Republican · MS
Eugene Vindman
Democrat · VA
Young Kim
Republican · CA
Nicole Malliotakis
Republican · NY
George Latimer
Democrat · NY
Cosponsor Coverage Map
Committee Sponsors
Ways and Means Committee
14 of 45 committee members cosponsored
Energy and Commerce Committee
20 of 54 committee members cosponsored
36 Republicans across these committees haven't cosponsored yet. Mobilize their constituents
H.R. 6130 Quick Facts
- Committee
- Ways and Means
- Chamber
- House
- Policy
- Health
- Introduced
- Nov 19, 2025
Referred to Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. for review
Nov 19, 2025
Official Sources
Official bill page with status, text, sponsors, and committee actions for H.R. 6130.
Official U.S. Code page for the Medicare definitions section that H.R. 6130 amends to add a new covered screening-test category.
FDA page explaining the 510(k) clearance pathway referenced in the bill as one qualifying federal review route.
FDA page describing the De Novo classification pathway under section 513(f)(2), which the bill names as another qualifying review pathway.
FDA page for the PMA approval process under section 515, another FDA pathway a test may use to qualify under the bill.
Official CMS payment page for the Clinical Laboratory Fee Schedule, relevant because the bill would pay covered tests through Medicare’s existing laboratory payment system.
H.R. 6130 Common Questions
What does H.R. 6130 do?
H.R. 6130 would make Medicare cover certain early detection tests for Alzheimer’s disease and related dementias, including qualifying blood-based tests, starting in 2028.
When would Medicare start covering these Alzheimer’s tests?
Coverage would begin for qualifying tests furnished on or after January 1, 2028.
Does H.R. 6130 cover blood tests for Alzheimer’s?
Yes. The bill specifically includes qualifying genomic sequencing blood or blood product tests for early Alzheimer’s and dementia detection.
Would Medicare cover tests before symptoms get severe?
Yes. The bill covers tests meant to detect the pre-symptomatic and early stage of Alzheimer’s disease or related dementias.
What kinds of tests could qualify besides blood genomic sequencing?
The bill says HHS could allow comparable tests, including single-analyte tests, cell-free nucleic acid analysis, multiplex panels, whole genome, protein expression, whole exome, whole transcriptome, and some medical imaging.
Do the tests need federal clearance or approval first?
Yes. A test must already be cleared, classified, or approved through an FDA pathway before Medicare coverage applies under H.R. 6130.
Would this be a temporary pilot program?
No. H.R. 6130 writes these screening tests directly into Medicare’s covered services, so it is set up as a permanent benefit category.
Does H.R. 6130 apply nationwide?
Yes. If enacted, H.R. 6130 would apply to Medicare nationwide, not just in one state.
Based on H.R. 6130 bill text
H.R. 6130 Bill Text
“To amend title XVIII of the Social Security Act to provide for Medicare coverage of blood-based dementia screening tests.”
Source: U.S. Government Publishing Office
Get notified when H.R. 6130 moves
Committee votes, floor action, cosponsor changes — straight to your inbox.
Bill alerts + Legisletter's monthly briefing. Unsubscribe anytime.
Health Bills
9 related bills we're tracking
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Reported (Amended) by the Committee on Ways and Means. H. Rept. 119-333, Part I.
Oct 3, 2025
Give Kids a Chance Act of 2025
Motion to reconsider laid on the table Agreed to without objection.
Dec 1, 2025
Improving Seniors’ Timely Access to Care Act of 2025
Forwarded by Subcommittee to Full Committee by Voice Vote.
Jun 25, 2026
CONNECT for Health Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jun 26, 2025
Momnibus Act
Referred to the Subcommittee on Health.
Apr 20, 2026
Right to Contraception Act
Referred to the House Committee on Energy and Commerce.
Feb 5, 2025
Women’s Health Protection Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jun 24, 2025
Medicare Patient Access and Practice Stabilization Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jan 31, 2025
EACH Act of 2025
Referred to the Subcommittee on Health.
Dec 19, 2025
Trending Right Now
Bills gaining momentum across Congress
Accelerating Access to Dementia and Alzheimer’s Provider Training Act
Placed on the Union Calendar, Calendar No. 628.
Jul 2, 2026
Ensuring Community Access to Pharmacist Services Act
Ordered to be Reported in the Nature of a Substitute by Voice Vote.
May 21, 2026
More Homes on the Market Act
Referred to the House Committee on Ways and Means.
Feb 13, 2025
Tracking Health in Congress? Monitor bills, track cosponsor momentum, and launch advocacy campaigns — all from one advocacy platform.